Zobrazeno 1 - 10
of 34
pro vyhledávání: '"M. Treitel"'
Autor:
Ellen G. J. Hulskotte, Hwa-Ping Feng, E. Hughes, Stephen P. Youngberg, Fengjuan Xuan, Joan R. Butterton, Edward O'Mara, Marga G. J. A. van Zutven, M. Treitel, John A. Wagner
Publikováno v:
Clinical Infectious Diseases. 56:718-726
BACKGROUND Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and ant
Autor:
Samir Gupta, M. Treitel, Claudia Kasserra, Richard A. Preston, William F. Feely, Ilias Triantafyllou, E. Hughes, Thomas Marbury, Edward O'Mara
Publikováno v:
Clinical Pharmacokinetics. 51:619-628
Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with chronic hepatitis C infection. The objective of this study was to evaluate the impact of impaired hepatic or renal func
Autor:
M. Davis, Patrick Marcellin, Anita Y. M. Howe, Jean-Pierre Bronowicki, Jonathan McCone, W. Deng, Stuart C Gordon, Eric M. Yoshida, John M. Vierling, Andrew J. Muir, Lisa D. Pedicone, Frans A. Helmond, Fred Poordad, Lynn Y. Colvard, Joseph S. Galati, Ira M. Jacobson, Janice K. Albrecht, Eric Lawitz, Clifford A. Brass, Steven L. Flamm, Velimir A. Luketic, Janice Wahl, M. Treitel
Publikováno v:
Journal of Hepatology
Journal of Hepatology, Elsevier, 2014, 60 (4), pp.748-756. ⟨10.1016/j.jhep.2013.12.013⟩
Journal of Hepatology, Elsevier, 2014, 60 (4), pp.748-756. ⟨10.1016/j.jhep.2013.12.013⟩
International audience; BACKGROUND & AIMS:Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0177022b53813e77c223b834a1790a53
https://hal.univ-lorraine.fr/hal-01687339
https://hal.univ-lorraine.fr/hal-01687339
Autor:
Stephanie Curry, John A. Howe, Maria J. Frontera, Richard J. O. Barnard, Donald J. Graham, Robert Chase, Frederick C. Lahser, E. Hughes, Anita Y. M. Howe, Patricia McMonagle, Marcelo Silva, Samir Gupta, M. Treitel
Publikováno v:
Journal of hepatology. 59(1)
Background & Aims To examine the antiviral activity of boceprevir, a hepatitis C virus (HCV) protease inhibitor, in HCV genotype (G) 2/3-infected patients. Methods We assessed boceprevir and telaprevir activity against an HCV G2 and G3 isolates enzym
Autor:
Janke Schinkel, H.L.A. Janssen, A. van Vliet, Richard Molenkamp, J.F. Bergmann, Christine J. Weegink, E. Hughes, R.J. de Knegt, M. Treitel, H. W. Reesink, J. de Bruijne
Publikováno v:
Journal of Hepatology. 52:S290-S291
Autor:
H.L.A. Janssen, Anther Keung, J.F. Bergmann, E. Hughes, A. van Vliet, H. W. Reesink, J. van Lier, Christine J. Weegink, Edward O'Mara, J. de Bruijne, Jianing Li, R.J. de Knegt, M. Treitel
Publikováno v:
Journal of Hepatology. 50:S35-S36
Autor:
M. Treitel, G. Zhuyan, Daria J. Hazuda, Anita Y. M. Howe, Rumin Zhang, Stephanie Curry, R.A. Ogert, Patricia McMonagle, Richard J. O. Barnard, J. Strizki, John A. Howe, Robert Chase, Donald J. Graham, Frederick C. Lahser
Publikováno v:
Journal of Hepatology. 56:S329
Autor:
S.C. Gordon, M. Treitel, W. Deng, S.L. Flamm, I. Jabobson, Joseph S. Galati, Patrick Marcellin, Jonathan McCone, E.J. Lawitz, Andrew J. Muir, John M. Vierling, Lisa D. Pedicone, Velimir A. Luketic, Eric M. Yoshida, M. Davis, Jean-Pierre Bronowicki, Janice Wahl, Fred Poordad
Publikováno v:
Journal of Hepatology. 56:S6
1University Henri Poincare of Nancy, Vandoeuvre-les-Nancy, France; 2South Florida Center of Gastroenterology, Wellington, FL; 3Northwestern Feinberg School of Medicine, Chicago, IL; 4Henry Ford Hospital, Detroit, MI; 5Alamo Medical Research, San Anto
Autor:
E. Hughes, Sanjeev Gupta, C. Hu, M. Corpus, Edward O'Mara, C. Xu, J. van Lier, D. Marchisin, B. Yue, A. van Vliet, P. Prasad, A. Sheth, M. Treitel
Publikováno v:
Journal of Hepatology. 50:S345
Autor:
K. Palaniappan, J. de Bres, M. Treitel, A. Sheth, Y. Wan, Sanjeev Gupta, C. Hu, P. Prasad, D. Marchisin, Edward O'Mara, A. Connor, E. Hughes, M. Corpus, B. Yue
Publikováno v:
Journal of Hepatology. 50:S345
Time After Dose Time After Colon Arrival Activation/ Capsule Recovery Interval Treatment D: MMN formulation activated in AC n 8 8 7 Mean (SD) 12.75 (6.50) 1.35 (2.37) 19.70 (5.69) Range 5.72-25.70 0.23-7.07 9.35-24.48 Treatment E: micronized formulat